Precigen, Inc. (PGEN): Price and Financial Metrics

Precigen, Inc. (PGEN): $1.29

0.13 (-9.15%)

POWR Rating

Component Grades








Add PGEN to Watchlist
Sign Up

Industry: Biotech




#257 of 356

in industry

PGEN Price/Volume Stats

Current price $1.29 52-week high $2.29
Prev. close $1.42 52-week low $0.81
Day low $1.29 Volume 930,500
Day high $1.43 Avg. volume 1,707,485
50-day MA $1.47 Dividend yield N/A
200-day MA $1.35 Market Cap 329.57M

PGEN Stock Price Chart Interactive Chart >


  • PGEN scores best on the Sentiment dimension, with a Sentiment rank ahead of 57.01% of US stocks.
  • The strongest trend for PGEN is in Growth, which has been heading down over the past 177 days.
  • PGEN's current lowest rank is in the Stability metric (where it is better than 9.19% of US stocks).

PGEN Stock Summary

  • With a year-over-year growth in debt of -96.17%, PRECIGEN INC's debt growth rate surpasses just 1.08% of about US stocks.
  • Revenue growth over the past 12 months for PRECIGEN INC comes in at -72.62%, a number that bests merely 2.75% of the US stocks we're tracking.
  • PRECIGEN INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 35.07%, greater than the shareholder yield of 94.55% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to PRECIGEN INC, a group of peers worth examining would be LGVN, RYTM, CYCN, TFFP, and ONVO.
  • Visit PGEN's SEC page to see the company's official filings. To visit the company's web site, go to

PGEN Valuation Summary

  • PGEN's EV/EBIT ratio is 13.9; this is 19.83% higher than that of the median Healthcare stock.
  • PGEN's price/sales ratio has moved down 2884 over the prior 123 months.

Below are key valuation metrics over time for PGEN.

Stock Date P/S P/B P/E EV/EBIT
PGEN 2023-09-22 16.2 2.2 16.1 13.9
PGEN 2023-09-21 16.2 2.2 16.1 13.9
PGEN 2023-09-20 16.2 2.2 16.1 13.9
PGEN 2023-09-19 15.3 2.0 15.2 13.1
PGEN 2023-09-18 16.6 2.2 16.6 14.3
PGEN 2023-09-15 17.2 2.3 17.2 14.8

PGEN Growth Metrics

    Its 3 year revenue growth rate is now at -22.78%.
  • The year over year revenue growth rate now stands at 13.83%.
  • The year over year net cashflow from operations growth rate now stands at 11.41%.
Over the past 33 months, PGEN's revenue has gone down $14,847,000.

The table below shows PGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 75.875 -64.238 25.459
2022-06-30 80.714 -57.447 -91.684
2022-03-31 111.383 -58.17 -94.099
2021-12-31 103.873 -55.771 -92.166
2021-09-30 98.985 -57.651 -108.793
2021-06-30 101.007 -59.633 -108.537

PGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PGEN has a Quality Grade of C, ranking ahead of 33.59% of graded US stocks.
  • PGEN's asset turnover comes in at 0.277 -- ranking 449th of 561 Business Services stocks.
  • V, GOVX, and CELP are the stocks whose asset turnover ratios are most correlated with PGEN.

The table below shows PGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.277 0.456 -0.241
2021-03-31 0.276 0.439 -0.310
2020-12-31 0.291 0.462 -0.418
2020-09-30 0.237 0.398 -0.717
2020-06-30 0.201 0.376 -0.731
2020-03-31 0.183 0.387 -0.659

PGEN Price Target

For more insight on analysts targets of PGEN, see our PGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.5 (Moderate Buy)

Precigen, Inc. (PGEN) Company Bio

Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.

PGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

PGEN Latest Social Stream

Loading social stream, please wait...

View Full PGEN Social Stream

Latest PGEN News From Around the Web

Below are the latest news stories about PRECIGEN INC that investors may wish to consider to help them evaluate PGEN as an investment opportunity.

While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership

Key Insights Precigen's significant private equity firms ownership suggests that the key decisions are influenced by...

Yahoo | September 25, 2023

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the following upcoming investor and industry conferences:

Yahoo | September 19, 2023

Fred Hassan Bought 185% More Shares In Precigen

Precigen, Inc. ( NASDAQ:PGEN ) shareholders (or potential shareholders) will be happy to see that the Independent...

Yahoo | August 17, 2023

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2023 financial results and business updates.

Yahoo | August 9, 2023

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has agreed that the ongoing Phase 1/2 single arm study (NCT04724980) of the first-in-class investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP) will serve as pivotal for the purpose of filing an accelerated appr

Yahoo | August 9, 2023

Read More 'PGEN' Stories Here

PGEN Price Returns

1-mo -28.73%
3-mo N/A
6-mo 31.86%
1-year -39.15%
3-year -65.60%
5-year -91.97%
YTD -15.13%
2022 -59.03%
2021 -63.63%
2020 86.13%
2019 -16.21%
2018 -43.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!